Both Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) and Intec Pharma Ltd. (NASDAQ:NTEC) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.
Valuation and Earnings
Demonstrates Protalix BioTherapeutics Inc. and Intec Pharma Ltd. earnings per share (EPS), gross revenue and valuation.
Table 2 provides Protalix BioTherapeutics Inc. and Intec Pharma Ltd.’s net margins, return on assets and return on equity.
Institutional and Insider Ownership
Roughly 9.74% of Protalix BioTherapeutics Inc. shares are held by institutional investors while 39.64% of Intec Pharma Ltd. are owned by institutional investors. Insiders held roughly 6.23% of Protalix BioTherapeutics Inc.’s shares. Insiders Comparatively, held 11.81% of Intec Pharma Ltd. shares.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Protalix